Glioblastoma multiforme is type of cancer which is aggressive and develops within the brain. Symptoms of glioblastoma multiforme are non-specific initially, which include headache, personality changes, nausea and also shows similar symptoms like stroke where there is poor blood flow to brain resulting in cell death. Worsening of symptoms of glioblastoma multiforme is rapid leading to unconsciousness. According to American Brain Tumor Association, glioblastoma multiforme represent 14.9% of brain tumors in year 2016.
Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/682
As there are no current treatment available for glioblastoma multiforme, the market growth is expected to rise positively in near future. The treatment provided nowadays to prevent the disease involves surgery followed by chemotherapy and radiation treatment. High dose of steroids helps to reduce brain swelling symptom. Supply of various steroids in the market by the manufactures have failed to increase the survival rate. The common length of survival from diagnosis is 12 to 15 months with more or less 3% to 5% of people surviving longer than five years. The fact that glioma stem cells resist conventional treatment has raised the urgent need of alternative treatment or therapy, which favors the growth in glioblastoma multiforme market.
Glioblastoma multiforme market Taxonomy
By Therapy Type
By End User
- Cancer Research Organization
- Diagnostic Centers
- Long Term Care Centers
Rise in number of drugs in pipeline favors the glioblastoma multiforme market
High mortality rate due to glioblastoma multiforme has made it one of the lethal types of cancer, as nearly 17,000 people are estimated to die in year 2017 due to primary malignant and central nervous system brain tumor. According to American Brain Tumor Association, which provides information and treatment of brain tumors, nearly 80,000 new cases of primary brain tumor are diagnosed in year 2014 out of which approximately one-third or 32% of brain and CNS tumors are malignant in the U.S. They have also estimated that, there will be 12,390 new cases of glioblastoma multiforme in 2017 year. The pipeline of glioblastoma multiforme is well equipped with various types of novel therapies including immunotherapy, biologics, small molecules, and other drugs. The pipeline of glioblastoma multiforme is rich with number of therapeutic drugs and devices which are expected to receive FDA approval for the clinical trials. The FDA approved drugs for of glioblastoma multiforme currently are temozolomide that is Temodar, Temodal and Temcad; bevacizumab that is Avastin and carmustine wafers fuels the of glioblastoma multiforme market.
Regional growth engines for of glioblastoma multiforme market
The geographical segmentation under glioblastoma multiforme market consists North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. According to American Brain Tumor Association, nearly 700,000 people are living with a primary brain and central nervous system tumor in the U.S. in year 2014. Advances in healthcare research and rising awareness of glioblastoma multiforme in Asia Pacific is expected to rise the market of of glioblastoma multiforme. National Brain Tumor Society, American Brain Tumor Association, and Brain Tumor Foundation of Canada help to create awareness about glioblastoma multiforme treatment that is expected to favor the growth of glioblastoma multiforme market.
Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/682
The prominent key players in glioblastoma multiforme market
Increase in research and development in gene therapy and molecular biology for treatment of glioblastoma multiforme is expected to fuel the competition between various manufacture to lead the market. The key players operating in this market are Teva Pharmaceutical Industries, Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., and F. Hoffmann-La Roche AG.
This post was originally published on Trading Herald